Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Acute Myeloid Leukemia (AML) Patients with Myelodysplasia (MDS) Related-Gene Mutations in First Complete Remission (CR1) Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Ayman Sayyed, Taehyung Simon Kim, Silvia Park, Jae-Sook Ahn, Aly Karsan, Marie-France Gagnon, Julie Bergeron, Hee-Je Kim, Hyeoung-Joon Kim, David Sanford, Andre C. Schuh, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4954.

https://doi.org/10.1182/blood-2023-191011

Published: 2023

Journal Articles

The Presence of Somatic Mutations on Specific Pathways Such As Chromatin Modifier, Spliceosome, and Myeloid Transcription Factor at Diagnosis Was Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in 1,228 Patients with Acute Myeloid Leukemia in First Complete Remission (CR1)

Ayman Sayyed, Taehyung Simon Kim, Silvia Park, Jae-Sook Ahn, Aly Karsan, Marie-France Gagnon, Julie Bergeron, Hyeoung-Joon Kim, Heeje Kim, David Sanford, Andre C. Schuh, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4949.

https://doi.org/10.1182/blood-2023-190545

Published: 2023

Journal Articles

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Blood (2023) 142 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2023-189648

Published: 2023

Journal Articles

Is Allogeneic Hematopoietic Stem Cell Transplant (HCT) in First Remission Beneficial to Acute Myeloid Leukemia (AML) Patients with Isocitrate Dehydrogenase(IDH) Mutations?

Ayman Sayyed, Taehyung Simon Kim, Silvia Park, Jae-Sook Ahn, Aly Karsan, Marie-France Gagnon, Julie Bergeron, Hyeoung-Joon Kim, Heeje Kim, David Sanford, Andre C. Schuh, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4960.

https://doi.org/10.1182/blood-2023-191113

Published: 2023

Journal Articles

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Jacqueline S. Garcia, Eric S. Winer, Ilene Galinsky, Julie Bergeron, Julie Asch, Matthew D. Seftel, Richard M Stone, Marlise R. Luskin, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 4238.

https://doi.org/10.1182/blood-2023-181014

Published: 2023

Journal Articles

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Blood (2022) 140 (25): 2754–2756.

https://doi.org/10.1182/blood.2022016963

Published: 2022

Includes: Supplemental data

Journal Articles

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Blood (2022) 140 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2022-171751

Published: 2022

Journal Articles

Efficacy, Toxicity and Cost of Venetoclax-Based Combinations for the Treatment of Acute Myeloid Leukemia: Real-World Evidence from a Canadian Academic Center

Philippe Bouchard, Annie Brisebois-Boyer, Anne Beaudry, Jean-Francois Berthiaume, Nadia M. Bambace, Léa Bernard, Josee Hebert, Julie Bergeron

Blood (2021) 138 (Supplement 1): 1253.

https://doi.org/10.1182/blood-2021-149967

Published: 2021

Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Blood (2020) 135 (24): 2137–2145.

https://doi.org/10.1182/blood.2020004856

Published: 2020

Includes: Supplemental data

Journal Articles

Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia

Elizabeth F Krakow, MD MSc, Julie Bergeron, MD, Silvy Lachance, MD, Denis-Claude Roy, MD, Jean-Sebastien Delisle, MD PhD

Blood (2015) 126 (23): 2562.

https://doi.org/10.1182/blood.V126.23.2562.2562

Published: 2015

Journal Articles

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Daniel J. DeAngelo, MD PhD, Kristen Stevenson, MS, Donna S Neuberg, ScD, Lewis B. Silverman, MD, Karen K. Ballen, MD, Julie D. Asch, MD, Yasser Abou Mourad, MD, Kristjan Paulson, MD FRCPC, Matthew D. Seftel, MBChB, FRCP(C), MRCP, David Avigan, MD, Julie Bergeron, MD, Stephen Couban, MD, William Blum, MD, John Storring, MD, Martha Wadleigh, MD, David P. Steensma, MD, Jeffrey Supko, PhD, Stephen E. Sallan, MD, Richard M. Stone, MD

Blood (2015) 126 (23): 80.

https://doi.org/10.1182/blood.V126.23.80.80

Published: 2015

Journal Articles

Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts

Matthew D. Seftel, MDMPH FRCPC, Donna Neuberg, ScD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Julie Bergeron, MD FRCPC, Stephen Couban, MD FRCPC, Daniel J. DeAngelo, MD PhD, Marcos J de Lima, MD, Steven M. Devine, MD, Mary Eapen, MBBS, Mary M. Horowitz, MD MS, Marcelo C. Pasquini, MD MS, J. Douglas Rizzo, MD, Wael Saber, MD MS, Stephen E. Sallan, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD

Blood (2014) 124 (21): 319.

https://doi.org/10.1182/blood.V124.21.319.319

Published: 2014

Journal Articles

Acute Promyelocytic Leukemia In Canada: Poor Outcomes In Older Patients Remain

Matthew D. Seftel, MRCP, FRCPC, MPH, Anna Serebrin, MD, Pascal Lambert, MSc, Julie Bergeron, MD, Janeve Everett, MD, Andrea Kew, MD, David Jones, Catherine Meloche, Kristjan Paulson, MD, FRCPC, Mitchell Sabloff, MSc, MD, CM ,FRCP(C), Ismial Sherif, John Storring, MD, Donna Turner, Ph.D.

Blood (2013) 122 (21): 1714.

https://doi.org/10.1182/blood.V122.21.1714.1714

Published: 2013

Journal Articles

A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1

Hiba A Zahreddine, Biljana Culjkovic-Kraljacic, PhD, Sarit Assouline, MD, Abdellatif Amri, Patrick Gendron, M.Sc., Andrea A. Romeo, PhD, Stephen Morris, PhD, James Jaquith, PhD, Gregory Cormack, Eftihia Cocolakis, PhD, Julie Bergeron, MD, Leandro Cerchietti, MD, Brian Leber, MD, Wilson H. Miller, Jr., MD, PhD, Katherine LB. Borden, PhD

Blood (2013) 122 (21): 821.

https://doi.org/10.1182/blood.V122.21.821.821

Published: 2013

Journal Articles

Extensive molecular mapping of TCRα/δ- and TCRβ-involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T-ALL

Blood (2012) 120 (16): 3298–3309.

https://doi.org/10.1182/blood-2012-04-425488

Published: 2012

Includes: Supplemental data

Journal Articles

A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E,

Sarit Assouline, MD, Biljana Kraljacic-Culjkovic, PhD, Eftihia Cocolakis, PhD, Abdellatif Amri, Julie Bergeron, MD, Rahima Jamal, MD, Wilson H. Miller, Jr., MD, PhD, Katherine LB Borden, PhD

Blood (2011) 118 (21): 3606.

https://doi.org/10.1182/blood.V118.21.3606.3606

Published: 2011

Journal Articles

Outcome of Patients with Refractory Acute Leukemia Treated with a Third Induction Chemotherapy Regimen

Vincent Philippe Lavallée, MD, Claude Rondeau, TM, Josée Hébert, MD, Julie Bergeron, MD

Blood (2011) 118 (21): 4305.

https://doi.org/10.1182/blood.V118.21.4305.4305

Published: 2011

Journal Articles

Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs

Julie Bergeron, Emmanuelle Clappier, Isabelle Radford, Agnès Buzyn, Corinne Millien, Gwendoline Soler, Paola Ballerini, Xavier Thomas, Jean Soulier, Hervé Dombret, Elizabeth A. Macintyre, Vahid Asnafi

Blood (2007) 110 (7): 2324–2330.

https://doi.org/10.1182/blood-2007-04-079988

Published: 2007

Includes: Supplemental data

Journal Articles

Redefinition of TLX1-Positive T-ALLs.

Julie Bergeron, MD, Isabelle Radford, Pharm., Corinne Millien, Patrick Villarese, Elizabeth A. Macintyre, MD,PhD, Vahid Asnafi, MD,PhD

Blood (2006) 108 (11): 2285.

https://doi.org/10.1182/blood.V108.11.2285.2285

Published: 2006

Journal Articles

Notch1 Mutations in Adult T Lymphoblastic Lymphoma and T-ALL.

Frederic Baleydier, MD, Arnauld Simon, MD, Julie Bergeron, MD, Corinne Millien, Kheira Beldjord, MD, PhD, Stephane Lepretre, MD, Herve Dombret, MD, PhD, Vahid Asnafi, MD, PhD, Elizabeth A. Macintyre, MD, PhD

Blood (2006) 108 (11): 2286.

https://doi.org/10.1182/blood.V108.11.2286.2286

Published: 2006

NARROW

Acute Myeloid Leukemia (AML) Patients with Myelodysplasia (MDS) Related-Gene Mutations in First Complete Remission (CR1) Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Is Allogeneic Hematopoietic Stem Cell Transplant (HCT) in First Remission Beneficial to Acute Myeloid Leukemia (AML) Patients with Isocitrate Dehydrogenase(IDH) Mutations?

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Efficacy, Toxicity and Cost of Venetoclax-Based Combinations for the Treatment of Acute Myeloid Leukemia: Real-World Evidence from a Canadian Academic Center

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts

Acute Promyelocytic Leukemia In Canada: Poor Outcomes In Older Patients Remain

A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1

Extensive molecular mapping of TCRα/δ- and TCRβ-involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T-ALL

A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E,

Outcome of Patients with Refractory Acute Leukemia Treated with a Third Induction Chemotherapy Regimen

Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs

Redefinition of TLX1-Positive T-ALLs.

Notch1 Mutations in Adult T Lymphoblastic Lymphoma and T-ALL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only